PRESS RELEASE: Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting

Santhera Pharmaceuticals Holding AG / Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, April 23, 2012 - Santhera Pharmaceuticals (SIX: SANN) announced that all proposals at today's annual shareholders' meeting passed with a vast majority. Santhera's shareholders approved the annual report, the annual financial statements and the consolidated financial statements for 2011. Santhera's shareholders voted in favor of the proposed appropriation of the results, the renewal of authorized and the increase of conditional share capital. The annual shareholders' meeting also granted discharge to the members of the Board of Directors and management. Klaus Schollmeier and Timothy Rink were re-elected as Board members for a period of one and three years, respectively. The shareholders also re-elected Ernst & Young as auditors. A total of 1,691,639 shares or 46.05 % of the share capital was represented at the Annual Shareholders' Meeting.

In his presentation to shareholders, Thomas Meier, Chief Executive Officer, reported on significant progress with the Company's key projects and the impact of last year's restructuring: "In Europe, we submitted the application for marketing authorization of idebenone (Catena(®)) in Leber's Hereditary Optic Neuropathy (LHON). The revenues from product sales combined with strict cost control measures safeguarded Santhera's cash reserves." Looking into 2012 he continued: "We expect a decision from the European Medicines Agency on the LHON filing in the second half of the year. If approved, this would be our second product approval. With a significantly reduced cash burn the financing of Santhera's current business focus on key value drivers is secured into 2013."

* * *

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan neuromuscular and mitochondrial diseases, areas of high unmet medical with no current therapies. Santhera's first product Catena(®) is currently marketed in Canada to treat Friedreich's Ataxia. Catena(®) is also under review for marketing authorization by the European Medicine Agency as the first therapy for patients suffering from Leber's Hereditary Optic Neuropathy. For further information, please visit www.santhera.com.

Catena(®) is a trademark of Santhera Pharmaceuticals.

For further information, contact

Thomas Meier, Chief Executive Officer

Phone: +41 61 906 89 64

thomas.meier@santhera.com

Thomas Staffelbach, Vice President, Head Public & Investor Relations

Phone: +41 61 906 89 47

thomas.staffelbach@santhera.com

Disclaimer/Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any secu­rities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, un­certainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

--- End of Message ---

Santhera Pharmaceuticals Holding AG Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;

News release ASM 2012: http://hugin.info/137261/R/1604971/508013.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE [HUG#1604971]

http://www.santhera.com (END) Dow Jones Newswires

   April 23, 2012 08:33 ET (12:33 GMT)- - 08 33 AM EDT 04-23-12